Belantamab mafodotin in multiple myeloma

Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1043-1047. doi: 10.1080/14712598.2023.2218543. Epub 2023 May 27.

Affiliations

¹ Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza, Italy.
² Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Italy.
³ Scientific Directorate IRCCS of Reggio Emilia, Reggio Emilia, Italy.
⁴ Biotechnology Research Unit, AO of Cosenza, Cosenza, Italy.
⁵ Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

PMID: 37227998
DOI: 10.1080/14712598.2023.2218543

No abstract available

Keywords: Belantamab mafodotin; multiple myeloma; therapy.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Multiple Myeloma* / drug therapy

Substances

belantamab mafodotin
Antibodies, Monoclonal, Humanized